{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "GEOVAX LABS NEW  DL -,001", "longName": "GeoVax Labs, Inc.", "messageBoardId": "finmb_12056751", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -2.966382, "regularMarketPrice": 0.5888, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.8619461, "fiftyTwoWeekLow": 0.5086, "fiftyTwoWeekHigh": 4.265, "earningsTimestamp": 1683232200, "earningsTimestampStart": 1690887540, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.81, "epsForward": -1.27, "epsCurrentYear": -1.26, "priceEpsCurrentYear": -0.4673016, "sharesOutstanding": 26443600, "bookValue": 1.01, "fiftyDayAverage": 0.618652, "fiftyDayAverageChange": -0.029851973, "fiftyDayAverageChangePercent": -0.048253257, "twoHundredDayAverage": 0.9737435, "twoHundredDayAverageChange": -0.3849435, "twoHundredDayAverageChangePercent": -0.3953233, "marketCap": 15569992, "forwardPE": -0.46362206, "priceToBook": 0.5829703, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": -0.018000007, "regularMarketTime": 1683872225, "regularMarketDayHigh": 0.5888, "regularMarketDayRange": "0.5888 - 0.5888", "regularMarketDayLow": 0.5888, "regularMarketVolume": 5000, "regularMarketPreviousClose": 0.6068, "bid": 0.5912, "ask": 0.6146, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.5888, "averageDailyVolume3Month": 369, "averageDailyVolume10Day": 500, "fiftyTwoWeekLowChange": 0.08020002, "fiftyTwoWeekLowChangePercent": 0.1576878, "fiftyTwoWeekRange": "0.5086 - 4.265", "fiftyTwoWeekHighChange": -3.6762, "firstTradeDateMilliseconds": 1582009200000, "symbol": "E8L.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1900 Lake Park Drive", "address2": "Suite 380", "city": "Smyrna", "state": "GA", "zip": "30080", "country": "United States", "phone": "(678) 384-7220", "fax": "(678) 384-7281", "website": "https://www.geovax.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Mr. David Alan Dodd", "age": 72, "title": "Chairman, Pres & CEO", "yearBorn": 1950, "fiscalYear": 2022, "totalPay": {"raw": 469015, "fmt": "469.01k", "longFmt": "469,015"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark W. Reynolds CPA, CPA", "age": 60, "title": "CFO & Corp. Sec.", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 348200, "fmt": "348.2k", "longFmt": "348,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark J. Newman Ph.D.", "age": 67, "title": "Chief Scientific Officer", "yearBorn": 1955, "fiscalYear": 2022, "totalPay": {"raw": 364166, "fmt": "364.17k", "longFmt": "364,166"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Harriet Latham Robinson Ph.D.", "age": 84, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1938, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kelly T. McKee Jr., M.D., M.P.H.", "age": 72, "title": "Chief Medical Officer", "yearBorn": 1950, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jeffrey  Welch", "title": "Head of Process Devel. & Manufacturing Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}